The 16th round of negotiations for the Trans-Pacific Partnership Agreement (TPPA) took place at the Grand Copthorne Waterfront Hotel in Singapore in early March.
On March 27, from noon to 3 pm, the IP Policy Committee of TACD will hold a meeting on the intellectual property chapter of the proposed U.S.-European Union Transatlantic Trade and Investment Partnership (TTIP).
The meeting will be held at KEI’s offices at 1621 Connecticut Avenue NW, Suite 500, Washington, DC 20009
Today, 19 March 2013, the Supreme Court released its opinion in Kirtsaeng v. John Wiley & Sons, a case involving the parallel importation of copyrighted works. The case involved the petitioner, Kirtsaeng, purchasing textbooks in Thailand then reselling them in the United States. The Second Circuit held in this case that the first sale doctrine did not apply to foreign made goods, applying national exhaustion principles. Continue Reading →
On Monday, March 18, 2013, the National Institutes of Health (NIH), held a conference call with the four NGOs that filed an October 25, 2012 march-in request for the patents held by Abbott Laboratories/AbbVie relevant to the manufacture and sale of ritonavir, a federally funded invention that is much more expensive in the United States than in Canada, Europe or other high-income countries, and is only available as a co-formulated product with AbbVie’s version of lopinavir. Continue Reading →
On Tuesday, 5 March 2013, the Ambassador of Nepal made the following intervention at the World Trade Organization’s Council for TRIPS, on behalf of the LDC Group on agenda item 11, Request for an Extension of the Transitional Period under Article 66.1 of the TRIPS Agreement.
WTO Council for TRIPS Meeting, March 5-6, 2013
Agenda item 11 – Request for an Extension of the Transitional Period under Article 66.1 of the TRIPS Agreement
Presentation of Request (IP/C/W/583) by Nepal on Behalf of LDCs Group
LAW No. 1733/87 (FEK 171 A’ of 22.09.1987)
“Technology transfer, inventions, and technological innovation” as amended
by Art. 18, of Law No. 1739/1987 (FEK 201, A’ of 20.11.1987)
On 5 March 2013, the Government of India delivered the following statement at the TRIPS Council on agenda item 13, Intellectual Property and Innovation: Small and Medium-Sized Enterprises, a standalone item tabled by Chile, Chinese Taipei, the Republic of Korea and the United States of America.
We thank the delegations of Chinese Taipei, Korea, the United States and others for tabling an agenda item on “Intellectual Property and Innovation: Small and medium Sized Enterprises” which we understand is a standalone item.
KEI comment on the Medicines Patent Pool license and MoU with ViiV Healthcare
28 February 2013
FYI: James Love (james.love@keionline.org, +1.202.361.3040), Krista Cox (krista.cox@keionline.org, +1.202.332.2670) or Thiru Balasubramaniam (thiru@keionline.org).
The 27 February 2013 agreements between the Medicines Patent Pool (MPP) and ViiV Healthcare, a joint venture of GlaxoSmithKline, Pfizer, and Shionogi will expand access to affordable pediatric formulas for HIV/AIDS.
On January 8, 2013, the US Department of Justice (DOJ) and the U.S. Patent and Trademark Office (PTO) issued a joint statement on “remedies for standards-essential patents subject to voluntary F/RAND commitments. (Copy of statement here). Continue Reading →